|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Accounts receivable, net | ||||||||||||||||||||
| Non-trade receivable | ||||||||||||||||||||
| Related party receivable | ||||||||||||||||||||
| Related Party | ||||||||||||||||||||
| Total related party receivable | ||||||||||||||||||||
| Inventory | ||||||||||||||||||||
| Receivable for cash held back from the asset sale | ||||||||||||||||||||
| Receivable, related party | ||||||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||||||
| Current assets held for sale | ||||||||||||||||||||
| Total Current assets | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| Right-of-use assets | ||||||||||||||||||||
| Contract fulfillment assets | ||||||||||||||||||||
| Investment in DNA X LLC under equity method | ||||||||||||||||||||
| Identifiable intangible assets | ||||||||||||||||||||
| Deferred tax assets | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Non-current assets held for sale | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities and stockholders’ deficit | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued liabilities | ||||||||||||||||||||
| Warranty liability | ||||||||||||||||||||
| Current portion of lease liability | ||||||||||||||||||||
| Deferred revenue | ||||||||||||||||||||
| Promissory note, net, current portion | ||||||||||||||||||||
| Promissory notes, net | ||||||||||||||||||||
| Related Party | ||||||||||||||||||||
| Nonrelated Party | ||||||||||||||||||||
| Total promissory notes, net | ||||||||||||||||||||
| Derivative liability | ||||||||||||||||||||
| Income tax payable | ||||||||||||||||||||
| Current liabilities held for sale | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Long-term debt, less current portion | ||||||||||||||||||||
| Deferred tax liability | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Redeemable common stock | ||||||||||||||||||||
| Stockholders’ deficit | ||||||||||||||||||||
| Common stock, $0.001 par value per share; 1,000,000,000 shares authorized: and 1,488,268 and 1,265,067 shares issued and outstanding at June 30, 2026 and December 31, 2025 respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total stockholders’ deficit | ||||||||||||||||||||
| Total liabilities, redeemable common stock, and stockholders’ deficit | ||||||||||||||||||||
Loading...
